Choosing an appropriate salvage therapy for a patient with multiple myeloma

Click to increase image sizeClick to decrease image size

Declaration of interest

K Podar has received speaker’s honoraria from Celgene, Amgen Inc, and Janssen Pharmaceuticals. He has also received consultancy fees from Celgene and Janssen Pharmaceuticals. He has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

One referee declares that they’ve received honoraria from Janssen-Cilag, Celgene, Amgen, Takeda and Bristol-Myers Squibb.

Additional information

Funding

This manuscript was not funded.